• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by REGENXBIO Inc.

    4/8/25 4:20:03 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGNX alert in real time by email
    DEFA14A 1 rgnx-2025-proxy-addition.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    (Rule 14a-101)

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒ Filed by a party other than the Registrant ☐

    Check the appropriate box:
    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to §240.14a-12

    REGENXBIO Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 14a-6(i)(1) and 0-11


    img202572217_0.jpg

     

     


    img202572217_1.jpg

     


    Get the next $RGNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGNX

    DatePrice TargetRatingAnalyst
    2/11/2025$38.00 → $14.00Buy → Neutral
    Goldman
    2/7/2025$27.00Outperform
    Raymond James
    11/15/2024$22.00Overweight
    Morgan Stanley
    10/10/2024$18.00Outperform
    Raymond James
    6/7/2024$38.00Buy
    Goldman
    3/11/2024$36.00Buy
    H.C. Wainwright
    3/8/2024$20.00 → $35.00Sector Perform → Outperform
    RBC Capital Mkts
    3/6/2024$37.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $RGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/14/24 9:00:57 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/12/24 4:47:45 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

      SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

      11/4/24 1:49:56 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

      $150 million secured at closing extends cash runway into early 2027REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) and milestones from AbbVie ROCKVILLE, Md., May 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty (HCRx). This agreement monetizes select anticipated royalties and milestones, and provides both immediate and expected future, non-dilutive capital.  REGENXBIO received $150 million at closing, extending the Company's expected cash runway into early 2027. "This strate

      5/19/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

      PARAMUS, N.J., May 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) submission by REGENXBIO Inc. (REGENXBIO, Headquarters: Rockville, Maryland, USA, CEO: Curran M. Simpson, (REGENXBIO; Headquarters: Rockville, Maryland, USA; CEO: Curran M. Simpson, NASDAQ:RGNX) for RGX-121 (clemidsogene lanparvovec), a potential first-in-class, investigational gene therapy for the treatment of Mucopolysaccharidosis II (MPS II). The FDA granted REGENXBIO's BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") t

      5/14/25 7:13:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

      FDA assigns PDUFA target action date of November 9, 2025 RGX-121 on track to be the first gene therapy and one-time treatment for MPS IIPartner Nippon Shinyaku to lead commercialization upon potential approval REGENXBIO to lead commercial manufacturing and supply chainROCKVILLE, Md., May 13, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act

      5/13/25 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    SEC Filings

    See more
    • REGENXBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - REGENXBIO Inc. (0001590877) (Filer)

      5/19/25 4:15:15 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by REGENXBIO Inc.

      144 - REGENXBIO Inc. (0001590877) (Subject)

      5/12/25 4:29:06 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by REGENXBIO Inc.

      10-Q - REGENXBIO Inc. (0001590877) (Filer)

      5/12/25 4:15:25 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Financials

    Live finance-specific insights

    See more
    • REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026Pivotal trial more than half enrolled, with completion expected in 2025 Additional Phase I/II functional data expected 1H 2025 Initiating commercial supply manufacturing in Q3 2025FDA acceptance of Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121, partnered with Nippon Shinyaku) expected in May 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of surabgene lomparvovec (ABBV-RGX-314, partnered with AbbVie) in patients with wet age-related macular degeneration are expected in 2026 and planning of diabetic retinopathy pivotal study continuesConference call today at 4

      5/12/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mi

      4/30/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

      ROCKVILLE, Md., Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a leading

      2/26/25 4:05:00 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/6/24 6:29:00 PM ET
      $AMTM
      $APO
      $CMA
      $CRI
      Investment Managers
      Finance
      Major Banks
      Apparel
    • REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

      Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years.  "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and

      9/17/24 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • REGENXBIO Announces Leadership Transition

      Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE

      6/12/24 7:05:00 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • REGENXBIO downgraded by Goldman with a new price target

      Goldman downgraded REGENXBIO from Buy to Neutral and set a new price target of $14.00 from $38.00 previously

      2/11/25 7:12:20 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on REGENXBIO with a new price target

      Raymond James resumed coverage of REGENXBIO with a rating of Outperform and set a new price target of $27.00

      2/7/25 8:29:59 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on REGENXBIO with a new price target

      Morgan Stanley resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $22.00

      11/15/24 8:17:57 AM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mills Kenneth T. exercised 20,602 shares at a strike of $3.76 and sold $163,046 worth of shares (20,602 units at $7.91) (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      5/14/25 4:49:12 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Christmas Patrick J. covered exercise/tax liability with 4,700 shares, decreasing direct ownership by 3% to 156,110 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      4/4/25 5:17:19 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Pakola Steve covered exercise/tax liability with 5,263 shares, decreasing direct ownership by 2% to 210,717 units (SEC Form 4)

      4 - REGENXBIO Inc. (0001590877) (Issuer)

      4/4/25 5:17:02 PM ET
      $RGNX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care